Comparing of UroGen Pharma Ltd. (URGN) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS)

As Biotechnology businesses, UroGen Pharma Ltd. (NASDAQ:URGN) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS), are affected by contrast. This especially applies to their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
UroGen Pharma Ltd. N/A 1132.76 83.72M -4.79 0.00
Ionis Pharmaceuticals Inc. 752.47M 11.58 365.62M 2.58 25.76

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows us the return on assets, net margins and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
UroGen Pharma Ltd. 0.00% -70.2% -64.8%
Ionis Pharmaceuticals Inc. 48.59% 39.3% 14.4%

Liquidity

7.6 and 7.6 are the respective Current Ratio and a Quick Ratio of UroGen Pharma Ltd. Its rival Ionis Pharmaceuticals Inc.’s Current and Quick Ratios are 9.4 and 9.4 respectively. Ionis Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than UroGen Pharma Ltd.

Analyst Recommendations

Recommendations and Ratings for UroGen Pharma Ltd. and Ionis Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
UroGen Pharma Ltd. 0 2 0 2.00
Ionis Pharmaceuticals Inc. 0 2 1 2.33

The upside potential is 29.08% for UroGen Pharma Ltd. with consensus price target of $45.5. Ionis Pharmaceuticals Inc. on the other hand boasts of a $68.33 consensus price target and a 10.05% potential upside. The results from earlier shows that analysts view suggest that UroGen Pharma Ltd. seems more appealing than Ionis Pharmaceuticals Inc.

Insider and Institutional Ownership

Roughly 59.2% of UroGen Pharma Ltd. shares are owned by institutional investors while 85.4% of Ionis Pharmaceuticals Inc. are owned by institutional investors. About 1.3% of UroGen Pharma Ltd.’s share are owned by insiders. On the other hand, insiders owned about 0.2% of Ionis Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
UroGen Pharma Ltd. 3.45% 2.5% -3.01% -15.81% -36.28% -8.76%
Ionis Pharmaceuticals Inc. -3.06% -20.66% 9.91% 29.22% 43.49% 23.1%

For the past year UroGen Pharma Ltd. has -8.76% weaker performance while Ionis Pharmaceuticals Inc. has 23.1% stronger performance.

Summary

On 10 of the 12 factors Ionis Pharmaceuticals Inc. beats UroGen Pharma Ltd.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in RaÂ’anana, Israel.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.